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Abstract 
Introduction: Secretion of adrenomedullin (ADM) is stimulated by volume overload to maintain 
endothelial barrier function, and higher levels of biologically active (bio-) ADM in heart failure are a 
counteracting response to vascular leakage and tissue oedema. This study aimed to establish the 
value of plasma bio-ADM as a marker of congestion in patients with worsening heart failure (HF). 
Methods: The association of plasma bio-ADM with clinical markers of congestion, as well as its 
prognostic value was studied in 2,179 patients with new-onset or worsening HF enrolled in BIOSTAT-
CHF. Data were validated in a separate cohort of 1,703 patients. 
Results: Patient with higher plasma bio-ADM levels were older, had more severe HF and more signs 
and symptoms of congestion (all P<0.001). Amongst 20 biomarkers, bio-ADM was the strongest 
predictor of a clinical congestion score (r2=0.198). In multivariable regression analysis, higher bio-
ADM was associated with higher BMI, more edema, and higher FGF23. In hierarchical cluster 
analysis, bio-ADM clustered with edema, orthopnea, rales, hepatomegaly and JVP. Higher bio-ADM 
was independently associated with impaired uptitration of ACEi/ARBs after 3 months, but not of 
beta-blockers. Higher bio-ADM levels were independently associated with an increased risk of all-
cause mortality and HF hospitalization (HR: 1.16 (1.06-1.27), P=0.002, per log increase). Analyses in 
the validation cohort yielded comparable findings. 
Conclusions: Plasma bio-ADM in patients with new-onset and worsening HF is associated with more 
severe HF and more edema, orthopnea, hepatomegaly and JVP. We therefore postulate bio-ADM as 
a congestion marker, which might become useful to guide decongestive therapy.  
 
KEYWORDS: bio-ADM; pro-ADM; adrenomedullin; heart failure; congestion  
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Abbreviations 
ACEi   Angiotensin converting enzyme inhibitors 
ARB  Angiotensin receptor blockers 
Bio-ADM Biologically active adrenomedullin 
BIOSTAT-CHF A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure 
ET1  Endothelin 1 
FGF23  Fibroblast Growth Factor 23 
HF  Heart Failure 
IL6  Interleukin 6 
NT-proBNP N-terminal pro blood natriuretic peptide 
NYHA  New York Heart Association 
PENK  Pro-enkephalin 
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Introduction 
Pulmonary and systemic congestion play a major role in symptoms that are associated with 
worsening heart failure.(1, 2)  Consequently, patients who are hospitalized for worsening heart 
failure with a poor diuretic response and incomplete decongestion at discharge have a greater risk of 
death and hospital re-admission.(3, 4)  Therefore, an easy-to-use surrogate biomarker for the 
assessment of a patient’s congestion status might be of great clinical value.    
A promising novel biomarker in this context is the biologically active form of adrenomedullin (bio-
ADM), a 52-amino acid ringed vasodilatory peptide hormone that is elevated in acute and chronic 
heart failure.(5-8)  The adrenomedullin (ADM) gene encodes a preprohormone, which after cleavage 
generates a pro-ADM peptide, which by proteolytic fragmentation becomes a glycine-extended, 
inactive ADM. This is enzymatically converted to the biologically active ADM. Secretion of ADM has 
been demonstrated from endothelial cells, cardiac myocytes, vascular smooth muscle cells, and 
leucocytes. ADM is cleared by neutral endopeptidase, and through binding with its receptors. The 
most dominant role of ADM is thought to be the regulation of endothelial function, and ADM has 
been shown to play an essential role in maintaining endothelial barrier function and disruption 
hereof results in vascular leakage, and systemic and pulmonary edema.(9, 10)  ADM expression is 
stimulated by volume overload and increased plasma ADM reflects excessive fluid overload.(11)  In a 
recent study in patients with acute heart failure, bio-ADM at baseline was associated with more signs 
of congestion and higher bio-ADM levels after 7 days of decongestive treatment were associated 
with significant residual congestion at this time point.(7)  The findings from this study suggest that 
bio-ADM might be a potential marker of congestion both at admission and during/after a 
hospitalization for acute heart failure. In the current study, we aimed to further evaluate clinical and 
biological factors associated with bio-ADM in patients with worsening and new-onset heart failure, 
and assess associations with congestion and outcome, in order to gain greater insight in the potential 
role of bio-ADM in heart failure.  
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Methods 
Study population 
We studied plasma bio-ADM in patients enrolled in ‘A systems BIOlogy Study to Tailored Treatment 
in Chronic Heart Failure’ (BIOSTAT-CHF), a multicenter, multinational, prospective observational 
study. In the BIOSTAT-CHF index cohort, 2,516 patients were enrolled with worsening signs and/or 
symptoms of heart failure from 11 European countries, who were on suboptimal guideline 
recommended treatment (i.e. ≤50% of target doses of angiotensin-converting enzyme (ACE) 
inhibitors/angiotensin receptor blockers (ARB) and beta-blockers). Patients could be enrolled as in- 
and outpatients, however the majority of patients were hospitalized for worsening heart failure. A 
number of patients were admitted or presented to the hospital for “other” reasons, yet developed 
worsening or new-onset heart failure during hospitalization. Most frequent other reasons were 
rhythm disturbances, acute coronary syndrome, implantation of a device or uptitration of heart 
failure medication. Patients should have objective evidence of cardiac dysfunction documented by 
either left ventricle ejection fraction ≤40% or a blood natriuretic peptide (BNP) level ≥400 pg/ml or N-
terminal proBNP (NT-proBNP) ≥2000 pg/ml during screening. During the first three months after 
enrollment, investigators were expected to optimize treatment of heart failure with ACEi/ARB and 
beta-blockers, according to the doses indicated in the 2008 European Society of Cardiology 
Guidelines.(12) 
The results were subsequently validated in the BIOSTAT-CHF validation cohort, in which 1,738 
patients were recruited from six centers in Scotland, United Kingdom. In summary, in- and 
outpatients diagnosed with HF with a previous admission for heart failure and maintenance dose of 
≥20 mg of furosemide per day were eligible for enrollment. Details on both cohorts have been 
previously published.(13-16)  
All patients provided written informed consent to participate in the study and BIOSTAT-CHF was 
conducted in concordance with the declaration of Helsinki. The study was also approved by national 
and local ethics committees. 
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Study assessments 
Plasma bio-ADM was measured at baseline in 2,179 patients in the index cohort and in 1,703 patients 
in the validation cohort, using an immunoassay (sphingotest® bio-ADM®) developed by sphingotec 
GmbH (Hennigsdorf, Germany).(8, 17) Included patients were generally comparable to excluded 
patients for both cohorts (supplementary table 1 and 2). In brief, the bio-ADM immunoassay is a 1-
step sandwich chemiluminescence immunoassay based on Acridinium NHS-ester labeling for the 
detection of human adrenomedullin in unprocessed, neat plasma. It uses 2 mouse monoclonal 
antibodies, one directed against the midregion and the other directed against the amidated C-
terminal moiety of ADM. The assay uses 50 μL of plasma samples/calibrators and 220 μL of labeled 
detection antibody. Upon storage at room temperature, bio-ADM in EDTA plasma is stable for up to 
24 hours, and samples are unaffected by at least up to 4 freeze-thaw cycles. The analytical assay 
sensitivity is 2 pg/mL. The lower detection limit is 3 pg/mL, and intra- and interassay coefficients 
were 5-10%, and 4-8% respectively in the above normal measuring range. This assay is highly specific 
to bio-ADM as it only reacts with the mature amidated C-terminus of ADM, and not to other variants 
of (pro-)ADM.(17) In healthy subjects, median bio-ADM concentration was 20.7 pg/mL (99th 
percentile: 43 pg/mL).(18)  
A great number of other biomarkers from multiple pathophysiological domains, including markers of 
inflammation, apoptosis, remodeling, myocyte stress, angiogenesis, endothelial function and renal 
function were measured. Pro-enkephalin was measured using a sandwich immunoassay 
(sphingotest® penKid®) targeting PENK A amino-acids 119-159 developed by sphingotec GmbH 
(Hennigsdorf, Germany). Pro ADM was measured using a sandwich ELISA on a Luminex platform 
(Alere Inc., San Diego, CA, USA). Interleukin-6 (IL-6) and endothelin-1 were measured in frozen 
plasma by Singulex Inc. (Alameda, CA, USA) using high-sensitive single molecule counting (SMC™) 
technology (RUO, Erenna® Immunoassay System). NT-proBNP was measured using 
electrochemiluminescence on a Cobas e411 analyzer, using standard methods (Roche Diagnostics 
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GmbH, Mannheim, Germany). Measurement of other biomarkers was performed as previously 
described.(15, 19) From all available biomarkers, 20 were selected for these analyses based on their 
known involvement in volume overload, neurohormonal activation, renal function, and outcome 
(supplementary table 3). 
A congestion score was calculated as the sum of peripheral edema depending on the extent (0 to 1/3 
to 2/3 to 1), JVP (0 to 1), and orthopnea (0 to 1) for the index cohort. For the validation cohort, the 
maximum score is 2, as orthopnea was not routinely collected in this cohort.  A modified congestion 
score, where edema was scored 1 point, if edema extended above the knee, was used in a sensitivity 
analysis to balance the impact of edema on the congestion score.   
 
Outcomes 
The endpoints selected for these analyses were all-cause mortality, cardiovascular mortality, and the 
combined endpoint of all-cause mortality or first occurrence of HF hospitalization. Cardiovascular 
mortality was based on the narrative provided for each death by a small committee of cardiologists. 
Additionally, the association between bio-ADM and therapy optimization for ACEi/ARB and beta-
blockers at 3 months was evaluated.  
 
Statistical analysis 
Baseline clinical variables and biomarkers were evaluated over tertiles of bio-ADM levels. Frequency 
(percentage) was used to summarize categorical variables while normally distributed continuous 
variables were summarized with mean ± standard deviations (SD) and non-normally distributed 
continuous variables with median [interquartile range]. Trends over tertiles of bio-ADM were 
statistically tested with Cochran-Armitage trend test, Jonckheere-Terpstra or a linear regression 
model for categorical variables, non-normally distributed continuous variables, and normally 
distributed continuous variables, respectively. Uni- and multivariable linear regression analysis was 
performed with log transformed bio-ADM as a dependent variable. Transformations were checked 
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using multifractional polynomials. Multivariable linear regression analysis, including all variables with 
p<0.10 in univariable analysis were constructed via backward elimination and validated using 
bootstrap re-sampling with 1,000 replicates. The model was tested for collinearity and checked by 
plotting residuals. The correlation heat maps and dendrograms were constructed using the ggplot2, 
reshape2, fastcluster, Hmisc, and sparcl packages in R. Cox proportional hazard regression analysis 
was performed to examine associations with clinical outcomes. Bio-ADM was investigated as a 
continuous variable, and by quintiles. Multivariable models were adjusted for an outcome model 
specifically developed and validated in the BIOSTAT index and validation cohort.(14)  The added 
value of bio-ADM for estimating the risk of poor outcome was assessed by examining gain in Harrell’s 
C-index (a measure of model discrimination, higher values are better), using likelihood ratio tests for 
nested survival models, and assessment of continuous net reclassification improvement (NRI, a 
category-independent measure quantifying the degree of improvement in model-based risk 
estimates obtained by adding a marker to a model). Logistic regression was used to investigate the 
association between bio-ADM and ACEi/ARB use, and whether target dose was reached. A two-tailed 
p-value <0.05 was considered statistically significant. All analyses were performed using R: A 
Language and Environment for Statistical Computing, version 3.3.1 (R Foundation for Statistical 
Computing, Vienna, Austria). 
 
Results 
Patient characteristics 
Median bio-ADM at baseline was 33.8 [22.6-53.9] pg/mL. Baseline characteristics over tertiles of bio-
ADM are presented in table 1. Patients with higher bio-ADM levels were older, had a higher BMI, and 
more severe heart failure (higher New York Heart Association (NYHA) class, higher NT-proBNP levels 
and more frequently a past heart failure hospitalization), all P<0.006. Additionally, higher bio-ADM 
levels were associated with the presence of signs and symptoms of congestion, lower systolic and 
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diastolic blood pressure, poorer renal function, and higher levels of biomarkers such as fibroblast 
growth factor (FGF) 23, pro-enkephalin (PENK), and interleukin (IL) 6, all P<0.009. Interestingly, 
patients with higher bio-ADM levels used higher doses of diuretics (P<0.001). After 9 months, 
patients in the highest tertile were more likely to use loop diuretics (98.2% versus 92.2%, P=0.018 for 
first versus third tertile), and used slightly higher doses (40 [40-50] mg versus 60 [40-125] mg of 
furosemide or equivalent, P<0.001 for first versus third tertile).  
 
Association between bio-ADM and clinical variables 
The result of multivariable linear regression analysis for log bio-ADM is shown in supplementary table 
4. The strongest associations with higher log bio-ADM were higher BMI, higher log FGF23, more 
frequent edema, higher interleukin-6 and endothelin-1 (r2=0.580). Log pro-ADM was significantly 
associated with log bio-ADM levels yet explained only 30% of the variance of log bio-ADM. Pro-ADM 
was not significant in a multivariable model for bio-ADM; forcing this variable into the multivariable 
model increased the r squared significantly to 0.594, P<0.001.   
 
Correlation and network analysis 
The results of hierarchical clustering of variables and a correlation heat map are presented in figure 1 
and 2. The heat map (figure 1) illustrates that bio-ADM levels are most strongly correlated with 
FGF23 (Spearman’s rho: 0.57, P<0.001), pro-ADM (Spearman’s rho: 0.54, P<0.001), GDF-15 
(Spearman’s rho: 0.49, P<0.001), and the presence of edema (Spearman’s rho: 0.43, P<0.001). In a 
hierarchical cluster analysis (figure 2) bio-ADM clustered with edema, as well as orthopnea, rales, 
hepatomegaly and JVP - all signs of congestion. Interestingly, pro-ADM, did not cluster with bio-ADM, 
yet clustered with FGF23, GDF15, and NT-proBNP. 
 
Bio-ADM and congestion  
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Amongst 20 markers, bio-ADM was the strongest variable associated with a higher clinical congestion 
score (r2=0.198, P<0.001), compared with for instance pro-ADM (r2=0.120, P<0.001), and NT-proBNP 
(r2=0.114, P<0.001). The modified congestion score yielded similar findings. This was also observed 
for the presence of edema where bio-ADM had an AUC of 0.768, compared to 0.658 for pro-ADM, 
and 0.641 for NT-proBNP. Other signs and symptoms of congestion such as JVP and orthopnea 
yielded comparable findings. In table 2, we show the comparison between associations of bio-ADM 
and NT-proBNP with clinical markers of congestion. In particular, the association between bio-ADM 
and edema was stronger than the association between NT-proBNP and edema. The distribution of 
bio-ADM over quartiles of NT-proBNP (for both cohorts) is plotted in supplementary figure 1. Using 
ROC analysis, the best cutoff value of bio-ADM to assess congestion (defined as a congestion score > 
1) was 34 pg/mL.  
 
Bio-ADM and therapy optimization 
Higher levels of log bio-ADM were associated with lower rates of ACEi/ARB and beta-blocker use at 
baseline (table 1). Also, patients with higher bio-ADM levels less frequently used guideline-
recommended doses of ACEi/ARBs and beta-blockers (table 1). Furthermore, higher bio-ADM levels 
were inversely associated with ACEi/ARB use and dosage after 3 months of uptitration (table 3). This 
association remained significant after adjustment for body mass index, FGF23, PENK, NT-proBNP, 
estimated glomerular filtration rate, age, sex, edema and ACE/ARB or beta-blocker use at baseline. In 
contrast, there was no significant independent association between bio-ADM levels and beta-blocker 
dosage after 3 months of uptitration.  
 
Bio-ADM and outcomes 
During a median follow-up of 21 [15-27] months, 583 (26.7%) patients died and 914 (41.9%) patients 
experienced the combined endpoint of all-cause mortality or heart failure hospitalization. In 
univariable Cox regression analysis log bio-ADM was significantly associated with an increased risk of 
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all-cause mortality (HR 1.79 [1.63-1.97], P<0.001 per log increase), and the combined endpoint (HR: 
1.71 [1.58-1.85], P<0.001 per log increase). This remained significant for both endpoints after 
adjustment for the BIOSTAT risk model (table 4), as well as after adjustment for the BIOSTAT risk 
model with addition of NT-proBNP and the clinical congestion score (HR: 1.19 [1.03-1.36], P=0.015 
per log increase for the combined endpoint). The association of bio-ADM with outcome was also 
analyzed over quintiles of bio-ADM, where after multivariable adjustment quintile 4 and 5, i.e. the 
highest bio-ADM levels, remained significantly associated with an increased risk of adverse outcome 
(table 3). Kaplan Meier curves for all-cause mortality per quintile of bio-ADM are shown in figure 3, 
illustrating a higher risk over increasing quintiles of bio-ADM (log rank P<0.001). Higher levels of bio-
ADM were independently associated with an increased risk of cardiovascular mortality (HR 1.27 
[1.04-1.56], P=0.020 per log increase).  
When comparing the predictive value of NT-proBNP to bio-ADM for outcome, NT-proBNP was a 
stronger predictor of all-cause mortality (univariable c-index 0.673 for NT-proBNP versus 0.636 for 
bio-ADM), as well as the combined endpoint (univariable c-index 0.652 for NT-proBNP versus 0.624 
for bio-ADM). Bio-ADM did not improve the net reclassification index on top of the BIOSTAT risk 
model (including NT-proBNP) for both outcomes (supplementary table 5).   
 
Validation of bio-ADM 
The value of bio-ADM in worsening or new-onset heart failure was subsequently validated in a 
separate cohort of 1,703 heart failure patients. Median bio-ADM was 27.3 [18.0-42.1] pg/mL. 
Baseline characteristics over tertiles of bio-ADM in the validation cohort are shown in supplementary 
table 6. The strongest associations with higher bio-ADM levels in multivariable linear regression 
analysis were observed for edema, higher levels of urea, PENK and higher heart rate (adjusted 
r2=0.357) (supplementary table 7).  
Correlation and network analysis 
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The heat map (supplementary figure 2) illustrates that bio-ADM levels are most strongly correlated 
with the clinical congestion score (Spearman’s rho: 0.37, P<0.001), the presence of edema 
(Spearman’s rho: 0.34, P<0.001), and creatinine (Spearman’s rho: 0.34, P<0.001). Again, the modified 
congestion score yielded similar findings. In a hierarchical cluster analysis (supplementary figure 3) 
bio-ADM clustered with NT-proBNP, and diastolic blood pressure. When for the index cohort exactly 
the same variables as in the validation cohort are entered into a heat map and hierarchical cluster 
analysis, bio-ADM clustered with edema, JVP, hepatomegaly, and the clinical congestion sore 
(supplementary figure 4 and 5).  
Bio-ADM and outcomes 
In the validation cohort during a median follow-up of 21 [12-33] months, 519 (30.5%) patients died 
and 715 (42.0%) experienced the combined endpoint. Cox regression analyses for (quintiles of) bio-
ADM yielded comparable findings to the index cohort (supplementary table 8, supplementary figure 
6). Similar to the index cohort, when comparing the prognostic value of bio-ADM to NT-proBNP, NT-
proBNP was a stronger predictor of both endpoints.  
 
 
Discussion  
In patients with new-onset and worsening heart failure, higher levels of plasma bio-ADM were 
strongly associated with more severe heart failure, and signs and symptoms of congestion, and 
independently associated with an increased risk of all-cause mortality and heart failure 
hospitalization. Using network analysis tools, such as hierarchical cluster analysis, bio-ADM clustered 
with markers of congestion. Interestingly, patients with higher bio-ADM levels were less likely to 
receive target doses of ACEi/ARB after 3 months of uptitration. These findings were externally 
validated in a separate cohort of patients with heart failure.  
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Bio-ADM as a marker of congestion 
Bio-ADM is vasodilatory peptide hormone that has been shown to play an essential role in 
maintaining endothelial barrier function, and disruption of this regulatory system results in vascular 
leakage, and systemic and pulmonary edema.(9) Adrenomedullin acts both intravascular as well as in 
the interstitium. Intravascular adrenomedullin acts on the endothelial cells and improves vascular 
integrity and decrease vascular permeability, whereas interstitial adrenomedullin causes vasodilation 
through its effect on vascular smooth muscle cells.(20)  Furthermore, the expression of ADM is 
stimulated by volume overload, and vice versa increased plasma ADM reflects excessive fluid 
overload.(11) These elevated levels bio-ADM in heart failure are reflective of a counteracting 
response to volume overload, as an attempt to limit tissue fluid overload by stabilizing the 
endothelial barrier function. We recently showed that in patients with acute heart failure, bio-ADM 
at baseline was strongly associated with signs and symptoms of congestion.(7) Interestingly, higher 
bio-ADM levels after 7 days of decongestive treatment were associated with significant residual 
congestion, this was not observed for NT-proBNP. These findings suggest that bio-ADM might be a 
marker of congestion, that provides additional information over NT-proBNP and could possibly be 
used to guide decongestive therapy. In this study in patients with new-onset or worsening heart 
failure slightly lower levels of bio-ADM were observed compared to the previous study in patients 
with acute heart failure (median bio-ADM 33.8 vs 44.1). This might confirm that in patients with 
more fluid overload, i.e. acute heart failure, bio-ADM levels are more elevated. In the present study 
however, bio-ADM levels were increased compared to healthy controls where a median value of 20.7 
has been described.(18)  
Despite the fact that this study investigated patients with new-onset or worsening heart failure with 
less fluid overload, the strong association of bio-ADM with congestion is evident. In hierarchical 
cluster analysis bio-ADM, as the only biomarker, clustered with symptoms of congestion. The slight 
difference in results between the index and validation cohort, might be due to the fact that patients 
in the validation cohort were generally less congested and for instance had significantly lower NT-
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proBNP levels. Yet, compared to NT-proBNP, bio-ADM was a stronger predictor of a clinical 
congestion score in both cohorts, and for the presence of edema in particular. The association of bio-
ADM with congestion is further supported by the finding that patients with higher bio-ADM levels 
used higher doses of loop diuretics and were more likely to use loop diuretics after 9 months of 
follow-up. In addition to an association with congestion markers, bio-ADM also showed a strong 
association to FGF23. FGF23, is a phosphaturic hormone, that is associated to renin-angiotensin-
aldosterone activation and has been postulated as a regulator of sodium hemostasis through 
upregulation of the sodium-chloride co-transporter in the distal tubule.(21) As such the association 
of bio-ADM with FGF23 might be indicative of congestion and could also suggest less effective 
decongestive therapy. Using ROC analyses, the best cut-off for bio-ADM to assess congestion was 34 
pg/mL, which is well above the median described in healthy volunteers, and if confirmed in future 
studies could be used to identify a patient with (residual) congestion. As congestion is notoriously 
difficult to assess reliably and interobserver variability is considerable, there is a great need for 
(bio)markers, that aid in reliable assessment of congestion. Our study suggests that bio-ADM is a 
biomarker that might have unique characteristics in this aspect, and could have clinical utility in a 
broad range of heart failure patients, i.e. from new-onset to acute heart failure. Future studies, 
preferentially using more objective measures to assess congestion, such as echography, in addition 
to physical examination will have to show whether bio-ADM does indeed provide additional 
information on top of this. Interestingly, patients with higher bio-ADM levels were less well 
uptitrated with ACEi or ARBs, which may be due to possible residual congestion and diuretic use, or 
more severe heart failure, hypotension and hemodynamic intolerance of these drugs. The 
association of bio-ADM with ACEi or ARB uptitration after 3 months was however independent of 
several markers of heart failure severity, such as NT-proBNP, and baseline use of ACEi or ARB.  
 
Bio-ADM as a marker for clinical outcome 
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In the current study, we found that higher bio-ADM levels were independently associated with 
poorer clinical outcome in patients with new-onset and worsening heart failure. This finding confirms 
previous studies that reported added prognostic value of bio-ADM for shorter-term outcomes.(7, 8, 
22)  We also found that higher levels of bio-ADM were independently associated with an increased 
risk of the combined endpoint, which includes both all-cause mortality and heart failure 
hospitalization. The strong association between higher levels of bio-ADM and a higher risk of hospital 
(re)admission is of particular interest, since the main cause of heart failure admissions for worsening 
heart failure is related to congestion.  The addition of bio-ADM to a model that included NT-proBNP 
did however not improve the net reclassification index. Therefore, the main value of bio-ADM might 
not be in predicting outcome, yet in its role as a congestion marker. As such it would have novel and 
additive value, compared to more established markers such as troponin or NT-proBNP. Taken 
together, our findings suggest that bio-ADM might be used to guide (decongestive) therapy, and 
possibly assess low risk of (re)hospitalization at discharge. Further studies in which bio-ADM is 
assessed at multiple time points during heart failure hospitalization might be able to shed more light 
on this.  
 
Adrenomedullin as a therapeutic target 
Finally, bio-ADM might be a modifiable risk factor, for instance by administering Adrecizumab, a 
humanized, monoclonal non-neutralizing antibody against the N-terminus of ADM, that increases 
plasma concentrations of bio-ADM in a dose-dependent manner.(23) In animal models of systemic 
inflammation and septic shock, Adrecizumab has shown promising results by improving 
hemodynamics and renal function.(23, 24) In heart failure, administration of Adrecizumab might 
result in improved vascular integrity with consequent improvement of tissue congestion and possibly 
outcomes.(20)  Of note, pharmacologic inhibition of neprilysin increased the plasma levels and 
potentiated the natriuretic and diuretic responses of ADM, when exogenously applied in a dog 
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model.(25) On that background it could be hypothesized that the beneficial effects of 
sacubitril/valsartan in heart failure might be partly explained by this mechanism. 
 
Bio-ADM and pro-ADM 
In this study, a relatively novel ADM assay was used that assesses biologically active ADM. Until 
recently ADM activity was measured using a biomarker that assessed an ADM precursor peptide 
(pro-ADM), which is in contrast to bio-ADM not the biologically active ADM. (17) In this study, pro-
ADM explained merely 30% of the variance in bio-ADM levels. Hierarchical clustering showed that 
pro-ADM did not cluster with bio-ADM or with congestion markers, yet with FGF23 and GDF-15. This 
suggests that bio-ADM and pro-ADM could provide insight in different underlying pathophysiological 
processes.  
 
Strengths and limitations 
This is the first study to assess the value of bio-ADM in patients with new-onset and worsening heart 
failure. Strengths of this study are the number of patients enrolled in this cohort, the validation in a 
separate cohort, as well as the extensive (bio)marker data available. Limitations of this study are the 
retrospective, observational design, the assessment of bio-ADM at one time point, and the lack of 
information regarding decongestion or decongestive treatment. Also, the congestion score used in 
this study is a modified score from the previously published congestion scores due to differences in 
recording of congestion variables.(26, 27)  Furthermore, bio-ADM was particularly strongly 
associated with easier to assess variables of congestion, i.e. edema and orthopnea, therefore, more 
objective markers to assess congestion, such as ultrasound, invasive hemodynamic measurements or 
plasma volume should be studied in subsequent studies. These were unfortunately not available in 
this dataset. However, at the moment there is no gold standard for the assessment of congestion in 
heart failure.(28)  Based on this study, only associations are described and causality cannot be 
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proven. (22, 23) Although bio-ADM was associated with clinical outcome in univariable models, there 
was no strong additive value on top of existing markers of clinical outcome.  
 
Future perspectives 
Future studies should assess the value of bio-ADM to guide (decongestive) treatment and might 
improve assessment of congestion in order to reliably establish euvolemia. Also, therapies aimed at 
increasing ADM levels, for instance by administration of Adrecizumab or neprilysin inhibitors, could 
be considered in order to improve outcomes.  
 
Conclusions 
Elevated plasma bio-ADM levels in patient with new-onset and worsening HF are associated with 
typical signs and symptoms of congestion and with an increased risk of mortality and heart failure 
hospitalization.  Bio-ADM might therefore be useful to guide decongestive therapy or might become 
a target for therapy.  
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Figure legends 
Figure 1: Biomarker position of bio-ADM depicted in a correlation heat map 
Abbreviations: BMI: Body Mass Index; bioADM: biologically active adrenomedullin; DBP: diastolic 
blood pressure; FGF23: fibroblast growth factor 23; GDF15: growth differentiation factor 15; GFR: 
glomerular filtration rate; HR: heart rate; JVP: jugular venous pressure; NGAL: neutrophil gelatinase 
associated lipocalin; NT-proBNP: n terminal pro blood natriuretic peptide; PENK: pro-enkephalin; 
proADM: pro-adrenomedullin; SBP: systolic blood pressure.  
 
 
Figure 2: Biomarker position of bio-ADM depicted in hierarchical cluster 
analysis 
 
Abbreviations: as in figure 1 
 
 
Figure 3: Kaplan-Meier curve for all-cause mortality for quintiles of bio-ADM 
in the index cohort 
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Table 1: baseline characteristics over tertiles of bio-ADM in the index cohort  
Tertile 1 Tertile 2 Tertile 3 P for  
trend 
N = 719 719 741   
bioADM (pg/mL) 19.2 [15.1-22.5] 33.3 [29.1-38.1] 67.2 [53.2-100.6]  
Demographics     
Sex (% Male(n)) 76.1 (547) 72.6 (522) 70.9 (525) 0.024 
Age (years) 66.9±12.5 69.4±11.7 70.4±11.7 <0.001 
Race (% Caucasian(n)) 98.9 (711) 98.7 (710) 99.1 (734) 0.756 
BMI (kg/m2) 25.8±4.3 27.8±5 29.9±6.3 <0.001 
Weight (kg) 76.1±15.6 81.3±16.7 87.7±21 <0.001 
Height (kg) 171.3±9.4 170.8±9.2 170.9±9.1 0.402 
NYHA class (%(n))    <0.001 
I 3.2 (23) 2.9 (21) 0.1 (1)  
II 47.4 (341) 38.4 (276) 20.4 (151)  
III 40.3 (290) 45.1 (324) 57.1 (423)  
IV 6.5 (47) 11.1 (80) 18.9 (140)  
LVEF (%) 30.5±9.4 31±10.7 31.9±12.2 0.015 
HFPEF (%(n)) 5.1 (35) 8.3 (53) 10.3 (65) <0.001 
Clinical Profile     
Edema (%(n)) 10.7 (60) 22.7 (131) 52.4 (349) <0.001 
Orthopnea (%(n)) 23.8 (171) 31.8 (228) 48.2 (356) <0.001 
Rales > 1/3 up lung fields (%(n)) 16.8 (48) 19.6 (76) 22 (103) 0.084 
Jugular venous pressure (%(n)) 21.1 (103) 31.5 (156) 49.4 (239) <0.001 
Hepatomegaly (%(n)) 8.5 (61) 12.8 (92) 20.8 (154) <0.001 
Third heart tone (%(n)) 10.6 (76) 8 (57) 11.1 (82) 0.731 
Clinical congestion score 0 [0-1] 0.67 [0-1.33] 1.67 [0.67-2.33] <0.001 
Systolic Blood Pressure (mmHg) 125.6±22.2 125.4±21.9 122.5±21.9 0.008 
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Diastolic Blood Pressure (mmHg) 76.1±12.8 75±13.8 72.9±13.1 <0.001 
Heart Rate (beats/min) 77±17.7 80.5±20.6 82.6±19.9 <0.001 
Hospitalization     
Type of visit (%(n))    <0.001 
Scheduled outpatient clinic 33.9 (244) 25.5 (183) 14.3 (106)  
Unscheduled outpatient clinic 6 (43) 3.9 (28) 3.6 (27)  
Inpatient hospitalization 60.1 (432) 70.7 (508) 82.1 (608)  
Reason for visit (%(n))    <0.001 
Worsening heart failure 45.1 (324) 51.9 (373) 63.8 (473)  
New-onset heart failure 30.6 (220) 30.5 (219) 26.5 (196)  
Other reason 24.3 (175) 17.7 (127) 9.7 (72)  
Diuretics iv (%(n)) 98.7 (310) 97.1 (372) 98.6 (545) 0.918 
Inotropics iv (%(n)) 10.9 (34) 8.9 (34) 13.2 (73) 0.195 
Nitrates iv (%(n)) 26.8 (83) 23.2 (89) 17.2 (95) 0.001 
Heart Failure History     
Years since first diagnosis 0.4 [0.1-1.3] 3 [0.3-8.8] 3.7 [0.7-7.2] 0.026 
Ischemic heart disease (%(n)) 56.2 (357) 62.6 (402) 61.6 (405) 0.048 
Hypertension (%(n)) 54.2 (371) 59.7 (410) 54.9 (389) 0.785 
Cardiomyopathy (%(n)) 52.8 (349) 38.7 (251) 38.7 (259) <0.001 
Valvular disease (%(n)) 37.1 (251) 40.5 (277) 44.4 (310) 0.006 
NYHA class prior to decompensation/worsening HF (%(n))    <0.001 
I 11 (79) 8.5 (61) 6.1 (45)  
II 51.6 (371) 46.6 (335) 40.4 (299)  
III 24.3 (175) 27.7 (199) 33.7 (250)  
IV 1.9 (14) 4 (29) 4.5 (33)  
Previous HF hospitalization (%(n)) 28.4 (204) 29.9 (215) 35.1 (260) 0.005 
Medical History     
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Hypertension (%(n)) 58.3 (419) 65.1 (468) 62.6 (464) 0.091 
Atrial fibrillation (%(n)) 33.4 (240) 46.2 (332) 57.2 (424) <0.001 
Coronary artery disease (%(n)) 38.1 (274) 46.5 (334) 47.1 (349) 0.001 
Myocardial infarction (%(n)) 32.8 (236) 39.5 (284) 38.3 (284) 0.031 
PCI (%(n)) 19.1 (137) 22 (158) 21.1 (156) 0.351 
CABG (%(n)) 11.7 (84) 17.5 (126) 21.7 (161) <0.001 
Pacemaker (%(n)) 5.7 (41) 9.5 (68) 7.2 (53) 0.301 
ICD (%(n)) 5.7 (41) 7.5 (54) 10.4 (77) 0.001 
Biventricular pacer (CRT) (%(n)) 1.3 (9) 1.3 (9) 3 (22) 0.014 
Biventricular Pacer (CRT) and ICD (%(n)) 5.4 (39) 6.1 (44) 8.6 (64) 0.014 
Diabetes mellitus (%(n)) 23.5 (169) 31.6 (227) 41.4 (307) <0.001 
COPD (%(n)) 13.1 (94) 18.2 (131) 20.2 (150) <0.001 
Peripheral artery disease (%(n)) 7.5 (54) 12.5 (90) 13.6 (101) <0.001 
Stroke (%(n)) 8.1 (58) 9.9 (71) 10.4 (77) 0.130 
Medication     
ACE-inhibitors or Angiotensin receptor blockers (%(n)) 78 (561) 73.2 (526) 64.2 (476) <0.001 
Target dose (%(n)) 14.9 (107) 12.4 (89) 10.9 (81) 0.024 
Beta-blockers (%(n)) 85.1 (612) 83.9 (603) 80.4 (596) 0.017 
Target dose (%(n)) 4 (29) 6.3 (45) 6.3 (47) 0.055 
Loop diuretics (%(n)) 99.3 (714) 99.6 (716) 99.6 (738) 0.436 
Loop diuretic dose (mg furosemide) 40 [40-62] 40 [40-80] 80 [40-150] <0.001 
Aldosterone antagonists (%(n)) 53.5 (385) 53.1 (382) 50.6 (375) 0.259 
Digoxin (%(n)) 16 (115) 18.9 (136) 20 (148) 0.050 
Laboratory     
Hemoglobin (g/dL) 13.7 [12.4-14.8] 13.4 [12.1-14.5] 12.7 [11.4-14] <0.001 
Creatinine (umol/L) 90.2 [76.9-112] 103.8 [87-125.6] 116 [93-153] 0.708 
Urea (mmol/L) 9.3 [6.7-14.7] 10.8 [7.5-17.4] 13.5 [8.8-23.8] <0.001 
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eGFR (ml/min/1.73m2) 71.1 [53.6-86] 58.6 [44.8-75.5] 49.7 [34.7-67.1] <0.001 
Sodium (mmol/L) 140 [138-142] 140 [137-142] 139 [136-141] <0.001 
Potassium (mmol/L) 4.3 [4-4.6] 4.2 [3.9-4.6] 4.2 [3.8-4.6] 0.003 
Calcium (mmol/L) 1.8 [1.5-2.1] 1.8 [1.5-2] 1.7 [1.4-2] <0.001 
Phosphate (mmol/L) 0.9 [0.7-1] 0.8 [0.7-1] 0.8 [0.7-1] 0.611 
Albumin (g/L) 34 [29-39] 32 [28-37] 31 [25-35] <0.001 
Iron (umol/L) 10 [6-14] 8.5 [6-12] 6 [4-10] <0.001 
Ferritin (ug/L) 116 [53.2-204.8] 106 [51.5-192] 81 [44-165] 0.057 
Transferrin (g/L) 2 [1.6-2.4] 2 [1.6-2.4] 2 [1.5-2.5] 0.890 
Aldosterone (pg/mL) 94 [43-187] 93 [44.5-180] 90 [42-211] 0.002 
Renin (UI/mL) 68 [23.9-191.7] 89.1 [27.6-229] 125.1 [36.2-374.5] <0.001 
NGAL 50.8 [33.0-80.2] 57.8 [35.7-88.3] 76.3 [45.6-125.4] <0.001 
Interleukin 6 (pg/mL) 3.4 [1.9-6.3] 4.9 [2.7-8.8] 8.6 [4.9-17] <0.001 
Troponin I (ng/L) 10.4 [5.9-22.8] 12.4 [6.6-27.7] 16.3 [9-33.2] 0.785 
Endothelin 1 (pg/mL) 4.5 [3.5-5.8] 5 [4-6.7] 6.7 [5.1-9] <0.001 
Fibroblast Growth Factor 23 (RU/mL) 132.3 [90.7-217.5] 201.9 [121.9-401.1] 621.9 [274.6-1745.6] <0.001 
Galectin 3 17.6 [13.0-25.0] 20.3 [15.5-28.0] 26.0 [18.8-36.7] <0.001 
Pro-enkephalin (pmol/L) 73.7 [56.1-97.6] 85.1 [64.5-116.4] 105 [77.2-151.1] <0.001 
Pro-ADM (ng/mL) 0.4 [0.2-0.5] 0.5 [0.3-0.7] 0.8 [0.5-1.3] <0.001 
NT-proBNP (pg/mL) 1826 [825-3959] 2563.5 [1142-5101.8] 4313 [2067-9355.5] <0.001 
GDF15 (pg/mL) 1974 [1306-2912] 2573 [1723.2-3980.2] 4324 [2694-7366] <0.001 
Abbreviations: ACE: angiotensin converting enzyme, bio-ADM: biologically active adrenomedullin, BMI: body mass index, CABG: coronary artery bypass 
graft, COPD: chronic obstructive pulmonary disease, CRT: chronic resynchronization therapy, eGFR: estimated glomerular filtration rate, GDF: growth 
differentiation factor, HF: heart failure, HFpEF: heart failure with a preserved ejection fraction, ICD: implantable cardiac defibrillator, LVEF: left ventricular 
ejection fraction, NT-proBNP: n-terminal pro blood natriuretic peptide, NYHA: New York heart association class, PCI: percutaneous coronary intervention, 
PENK: pro-enkephalin 
 
 
 
28 
 
 
 
Table 2: Comparison of associations with congestion variables between bio-ADM and NT-proBNP 
 
 Bio-ADM NT-proBNP P-value (comparison bio-
ADM vs NT-proBNP) 
 Correlation coefficient (r) P-value Correlation coefficient (r) P-value  
Edema (above knee) 0.43 <0.001 0.22 <0.001 <0.001 
Orthopnea 0.24 <0.001 0.17 <0.001 0.036 
JVP 0.29 <0.001 0.28 <0.001 0.767 
Third heart sound 0.03 0.168 0.05 0.039 0.630 
Hepatomegaly 0.16 <0.001 0.12 <0.001 0.157 
Rales 0.19 <0.001 0.20 <0.001 0.587 
Presented correlations are Spearman’s 
Abbreviations: bio-ADM: biologically active adrenomedullin, NT-proBNP: N-terminal pro blood natriuretic peptide 
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Table 3: bio-ADM and ACEi/ARB or beta blocker use after 3 months of uptitration in the index cohort 
 ACEi/ARB use  Target dose   Beta blocker use  Target dose  
Log bio ADM OR (CI) P-value OR (CI) P-value  OR (CI) P-value OR (CI) P-value 
Univariable 0.49 (0.42-0.57) <0.001 0.67 (0.57-0.78) <0.001  0.56 (0.47-0.66) <0.001 0.94 (0.79-1.12) 0.500 
Multivariable* 0.60 (0.47-0.79) <0.001 0.64 (0.47-0.87) 0.005  0.57 (0.42-0.77) <0.001 0.97 (0.70-1.33) 0.850 
* adjusted for BMI, FGF23, PENK, NTproBNP, eGFR, age, sex, edema, and ACE/ARB or beta blocker use at baseline 
Abbreviations: ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, bio-ADM: biologically active adrenomedullin, CI: 
confidence interval, OR: odds ratio 
 
 
 
 
Table 4: Cox regression analysis for bio-ADM and all-cause mortality, and the combined endpoint in the index cohort 
 
All-cause mortality 
   
Combined endpoint 
  
 
Univariable 
 
Multivariable* 
 
Univariable 
 
Multivariable# 
 
 
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Log bioADM 1.78 (1.62-1.95) <0.001 1.14 (1.02-1.28) 0.015 1.71 (1.58-1.85) <0.001 1.16 (1.06-1.27) 0.002  
        
Quintile 1 1.0 (Ref) Ref 1.0 (Ref) Ref 1.0 (Ref) Ref 1.0 (Ref) Ref 
Quintile 2 1.42 (1.02-1.96) 0.037 1.20 (0.87-1.66) 0.275 1.27 (0.99-1.61) 0.062 1.06 (0.83-1.35) 0.670 
Quintile 3 1.69 (1.23-2.31) 0.001 1.11 (0.80-1.53) 0.532 1.56 (1.23-1.97) <0.001 1.11 (0.88-1.41) 0.376 
Quintile 4 2.41 (1.79-3.26)  <0.001 1.35 (1.00-1.83) 0.056 2.06 (1.64-2.58) <0.001 1.23 (0.98-1.56) 0.076 
Quintile 5 3.82 (2.87-5.09) <0.001 1.39 (1.02-1.90) 0.036 3.23 (2.60-4.01) <0.001 1.33 (1.05-1.68) 0.019 
* adjusted for the BIOSTAT risk model for all-cause mortality (age, log blood urea nitrogen (BUN), log NT-proBNP, hemoglobin, and beta-blocker use at 
baseline) 
# adjusted for the BIOSTAT risk model for the combined endpoint (age, HF hospitalization in previous year, systolic blood pressure, log NT-proBNP, 
hemoglobin, high-density lipoprotein, sodium, and beta-blocker use at baseline) 
Abbreviations: bio-ADM: biologically active adrenomedullin, CI: confidence interval, HR: hazard ratio.   
 
